Compare IKT & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IKT | MRBK |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 220.5M |
| IPO Year | 2020 | 2018 |
| Metric | IKT | MRBK |
|---|---|---|
| Price | $1.73 | $18.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.3M | 65.4K |
| Earning Date | 05-13-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.99% |
| EPS Growth | ★ 67.51 | 30.34 |
| EPS | N/A | ★ 1.89 |
| Revenue | N/A | ★ $6,316,000.00 |
| Revenue This Year | N/A | $25.40 |
| Revenue Next Year | N/A | $8.15 |
| P/E Ratio | ★ N/A | $9.91 |
| Revenue Growth | N/A | ★ 10.13 |
| 52 Week Low | $1.33 | $11.17 |
| 52 Week High | $2.46 | $21.03 |
| Indicator | IKT | MRBK |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 47.16 |
| Support Level | $1.45 | $14.00 |
| Resistance Level | $1.79 | $19.24 |
| Average True Range (ATR) | 0.13 | 0.70 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 6.41 | 42.13 |
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.